Cargando…

Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation

Rivaroxaban is commonly used for prevention of thromboembolic diseases in patients with atrial fibrillation. We report a case of an 86-year-old man with hypertension, chronic kidney disease, type 2 diabetes mellitus, dyslipidemia, and atrial fibrillation who developed bullous eruptions 1 week after...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jiaming (Calvin), Raman, Karanvir, Chan, Siu Him, Tashakkor, A. Yashar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636228/
https://www.ncbi.nlm.nih.gov/pubmed/34888514
http://dx.doi.org/10.1016/j.cjco.2021.06.003
_version_ 1784608492405915648
author Liang, Jiaming (Calvin)
Raman, Karanvir
Chan, Siu Him
Tashakkor, A. Yashar
author_facet Liang, Jiaming (Calvin)
Raman, Karanvir
Chan, Siu Him
Tashakkor, A. Yashar
author_sort Liang, Jiaming (Calvin)
collection PubMed
description Rivaroxaban is commonly used for prevention of thromboembolic diseases in patients with atrial fibrillation. We report a case of an 86-year-old man with hypertension, chronic kidney disease, type 2 diabetes mellitus, dyslipidemia, and atrial fibrillation who developed bullous eruptions 1 week after a rivaroxaban dose increase. He was subsequently hospitalized, and direct immunofluorescence confirmed bullous pemphigoid (BP). After switching to apixaban, the patient's skin eruptions stabilized and improved. This is the first reported case of immunofluorescence-confirmed BP associated with rivaroxaban use. Prompt discontinuation of rivaroxaban and a switch to other anticoagulants is important for patients with suspected drug-associated BP.
format Online
Article
Text
id pubmed-8636228
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86362282021-12-08 Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation Liang, Jiaming (Calvin) Raman, Karanvir Chan, Siu Him Tashakkor, A. Yashar CJC Open Case Report Rivaroxaban is commonly used for prevention of thromboembolic diseases in patients with atrial fibrillation. We report a case of an 86-year-old man with hypertension, chronic kidney disease, type 2 diabetes mellitus, dyslipidemia, and atrial fibrillation who developed bullous eruptions 1 week after a rivaroxaban dose increase. He was subsequently hospitalized, and direct immunofluorescence confirmed bullous pemphigoid (BP). After switching to apixaban, the patient's skin eruptions stabilized and improved. This is the first reported case of immunofluorescence-confirmed BP associated with rivaroxaban use. Prompt discontinuation of rivaroxaban and a switch to other anticoagulants is important for patients with suspected drug-associated BP. Elsevier 2021-06-12 /pmc/articles/PMC8636228/ /pubmed/34888514 http://dx.doi.org/10.1016/j.cjco.2021.06.003 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Liang, Jiaming (Calvin)
Raman, Karanvir
Chan, Siu Him
Tashakkor, A. Yashar
Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation
title Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation
title_full Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation
title_fullStr Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation
title_full_unstemmed Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation
title_short Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation
title_sort rivaroxaban-associated bullous pemphigoid in a patient with atrial fibrillation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636228/
https://www.ncbi.nlm.nih.gov/pubmed/34888514
http://dx.doi.org/10.1016/j.cjco.2021.06.003
work_keys_str_mv AT liangjiamingcalvin rivaroxabanassociatedbullouspemphigoidinapatientwithatrialfibrillation
AT ramankaranvir rivaroxabanassociatedbullouspemphigoidinapatientwithatrialfibrillation
AT chansiuhim rivaroxabanassociatedbullouspemphigoidinapatientwithatrialfibrillation
AT tashakkorayashar rivaroxabanassociatedbullouspemphigoidinapatientwithatrialfibrillation